U.S. Markets closed

Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

Margaret Patrick
Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.